NAFTIFINE Drug Patent Profile
✉ Email this page to a colleague
When do Naftifine patents expire, and when can generic versions of Naftifine launch?
Naftifine is a drug marketed by Amneal, Sun Pharma Canada, and Xiromed. and is included in six NDAs.
The generic ingredient in NAFTIFINE is naftifine hydrochloride. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naftifine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Naftifine
A generic version of NAFTIFINE was approved as naftifine hydrochloride by SUN PHARMA CANADA on January 6th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NAFTIFINE?
- What are the global sales for NAFTIFINE?
- What is Average Wholesale Price for NAFTIFINE?
Summary for NAFTIFINE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for NAFTIFINE |
| DailyMed Link: | NAFTIFINE at DailyMed |
US Patents and Regulatory Information for NAFTIFINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | NAFTIFINE HYDROCHLORIDE | naftifine hydrochloride | CREAM;TOPICAL | 206960-001 | Apr 10, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Xiromed | NAFTIFINE HYDROCHLORIDE | naftifine hydrochloride | CREAM;TOPICAL | 210038-001 | Sep 22, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharma Canada | NAFTIFINE HYDROCHLORIDE | naftifine hydrochloride | CREAM;TOPICAL | 205975-001 | Sep 8, 2016 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharma Canada | NAFTIFINE HYDROCHLORIDE | naftifine hydrochloride | CREAM;TOPICAL | 206901-001 | Jan 6, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
